Bär & Karrer Ltd. | View firm profile
Today, Lonza and Sanofi announced that they have entered into a strategic
partnership to build and operate a large-scale mammalian cell culture facility for
monoclonal antibody production in Visp, Switzerland. The large-scale facility
will be established through a joint venture with an initial investment of
around CHF 290 million shared equally between Lonza and Sanofi. The initial construction
phase of the facility will commence in 2017, pending necessary regulatory
approvals. The facility is expected to be fully operational by 2020. The
partnership provides both
parties with substantial flexibility by using an innovative setup enabling them
to optimize biologics production capacity across the whole industry.
Bär & Karrer acts as legal advisor to Lonza. The team includes Urs
Kägi and Nadina Duss (both M&A/Corporate and Commercial), Mani Reinert
(Competition Law) and Markus Wang (IP).